Pulmonary hypertension (PH) is a malignant pulmonary vascular syndrome that leads to the right heart failure and even death. At present, the drugs for specific treatment are still limited. The existing targeted drugs are highly expensive, and drug treatment fails to meet clinical requirements. Comprehensive treatment of surgery, intervention and drug is urgently required.

Pulmonary artery denervation (PADN) for the treatment of pulmonary hypertension is originally established by Professor Chen Shaoliang from Nanjing Hospital affiliated to Nanjing Medical University in China, which has been gradually promoted to treat pulmonary hypertension at home and abroad. In 2022, it was recommended by the international authoritative guideline by "European Society of Cardiology/European Respiratory Society" (ESC/ERS). At the end of 2023, it was approved by China Food and Drug Administration (CFDA) in China. Currently, large-scale centers have gradually launched drug therapy combined with PADN to treat pulmonary hypertension.

On August 22, 2024, Professor Yuan Zuyi, President of Cardiovascular Disease Hospital, personally invited Professor Chen Shaoliang, the founder of PADN technology to perform PADN surgery for three patients with type I pulmonary hypertension in the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) (1 case of pulmonary hypertension after cardiac repair, 1 case of idiopathic pulmonary hypertension and 1 case of scleroderma-related pulmonary hypertension). FAH became one of the first-batch hospitals in China and the first hospital in northwest China to treat pulmonary hypertension with PADN.

Professor Wu Yue, Deputy Director of Department of Cardiovascular Medicine, chaired preoperative patient evaluation and case consultation. Professor Yuan Zuyi and Professor Chen Shaoliang led the team members of Professor Bai Ling and Professor Fan Fenling from Department of Cardiovascular Medicine to analyze clinical situation and previous treatment of this patient with pulmonary hypertension, and discuss the benefits of surgical risks, surgical approaches, intraoperative detection and evaluation, and postoperative treatment, etc. Under the arrangement of Head Nurse Mei Na from Interventional Operation Room, minimally invasive interventional PADN was performed for three patients with pulmonary hypertension. At the operation room, the patients' hemodynamic indexes and oxygenation capability were significantly enhanced. After the operation, breathing condition was significantly improved. All patients were discharged the next day after surgery.